Dr. Rudolph Widmann established AOP Orphan in Vienna in 1996 in order to provide individualized treatments for patients suffering from Rare Diseases. AOP Orphan has especially focused in the areas of hematology and oncology, cardiology, pulmonology, neurology, psychiatry and metabolic diseases.
Thanks to 15 years of experience in complex individualized treatments, AOP Orphan has obtained exceptional competence as well as market presence in the field of Orphan Diseases. The fact that AOP Orphan is privately owned assures a long-term engagement in the market along with high quality services and products. AOP Orphan is also the only provider of key therapies for certain special indications.
AOP Orphan experts work closely at an international level with leading health care professionals. This has given them the ability to react quickly towards needs and developments and to push research and development projects forward. When implementing these projects, AOP Orphan has a worldwide network of highly qualified partners that it can reach out to. These strategical alliances make sure that AOP Orphan as a middle-sized enterprise is able to compete with top-pharmaceutical companies.
AOP Orphan is currently one of the leading suppliers in the pharmaceutical industry, and as an international Austrian business, AOP Orphan generates sales of more than 50 million Euros. The company has an export quota of around 70% and over 100 employees. AOP Orphan’s branch offices are situated within its core markets in the EU, Switzerland, and the Middle East. Overall AOP Orphan has offices in 12 different regions. The international markets are handled and operated by close partners of AOP Orphan.
The company is led by the founder Dr. Rudolph Widmann, as well as Dr. Georg Fischer, Dr. Christoph Klade, Mag. Karin Pernkopf, Ms. Elfriede Gumplmayr and Douglas Lloyd-Fell.
Hematology & Oncology
In the branch of Hematology and Oncology, AOP Orphan focuses on myeloproliferative disorders—a group of malignant hematologic disorders that lead to the degeneration of the hematopoetic cells in the myeloid cell line.
Cardiology & Pulmonology
In the branch of cardiovascular diseases, AOP Orphan has specialized in two indications:
Neurology and Psychiatry
There are a small number of diseases located in the neurology region that are also considered Rare Diseases. AOP Orphan is focused on the diseases listed below:
In the branch of Metabolic Disorders, AOP Orphan focuses on those areas where there is a genetically determined or acquired enzyme deficit that triggers the disease— as is the case with Cystic Fibrosis (Mucoviscidosis).
AOP Orphan Pharmaceuticals AG
Mag. Daniela Gruber
T +43 1 503 72 44-42
F +43 1 503 72 44-61